http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022538138-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 2020-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022538138-A |
| titleOfInvention | CXCR4 inhibitors and uses thereof |
| abstract | The present invention relates to compounds and methods that inhibit CXC receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using said compositions in the treatment of various diseases. The compounds of the present invention, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof are useful for treating various diseases, disorders, and conditions associated with CXC receptor type 4 (CXCR4). Such diseases, disorders, and conditions include cell proliferative disorders (eg, cancer) such as those described herein. |
| priorityDate | 2019-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1745.